Effects of short-term treatment with mevalotin on platelet aggregation, fibrinolysis, peripheral serotonergic system and serum lipids in Japanese monkeys.

[1]  I. Shimoyama,et al.  Correlations between platelet aggregation, fibrinolysis, peripheral and central serotonergic measures in subhuman primates. , 1994, Atherosclerosis.

[2]  R. Knöfler,et al.  Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. , 1994, Thrombosis research.

[3]  M. Alessi,et al.  Plasminogen Activator Inhibitor 1 and Atherothrombosis , 1993, Thrombosis and Haemostasis.

[4]  J. Małyszko,et al.  Serotonergic measures in blood and brain and their correlations in rats treated with tranylcypromine, a monoamine oxidase inhibitor. , 1993, The Japanese journal of physiology.

[5]  H. Wada,et al.  Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. , 1992, Clinical therapeutics.

[6]  Y. Takada,et al.  Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus. , 1992, Thrombosis research.

[7]  N. Fetkovska.  Platelet Activation by Low‐Density Lipoprotein and Serotonin: Effects of Calcium Antagonists , 1992, Journal of cardiovascular pharmacology.

[8]  J. Jansson,et al.  Hypofibrinolysis in patients with hypertension and elevated cholesterol , 1991, Journal of internal medicine.

[9]  J. George,et al.  The clinical importance of acquired abnormalities of platelet function. , 1991, The New England journal of medicine.

[10]  P. Jones.  Lovastatin and simvastatin prevention studies. , 1990, The American journal of cardiology.

[11]  T. Urano,et al.  Relationships between Euglobulin Clot Lysis Time and the Plasma Levels of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor 1 , 1990, Thrombosis and Haemostasis.

[12]  G. Davı̀,et al.  Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients. , 1989, Atherosclerosis.

[13]  E. Steinhagen-Thiessen,et al.  Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia. , 1989, Eicosanoids.

[14]  T. Padró,et al.  Hyperlipemia, fibrinolysis and arteriosclerosis. , 1988, Thrombosis research.

[15]  D. Steinberg,et al.  Lipoproteins and the pathogenesis of atherosclerosis. , 1987, Circulation.

[16]  Y. Tsujita,et al.  CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. , 1986, Biochimica et biophysica acta.

[17]  R. Griffiths,et al.  The effect of 6‐oxo‐prostaglandin E1 on human platelet aggregation in whole blood in‐vitro , 1985, The Journal of pharmacy and pharmacology.

[18]  P. Vanhoutte.  Serotonin and the cardiovascular system , 1985 .

[19]  D. Cohen,et al.  Liquid-chromatographic determination of serotonin and tryptophan in whole blood and plasma. , 1981, Clinical chemistry.

[20]  H. Brewer,et al.  New micromethod for measuring cholesterol in plasma lipoprotein fractions. , 1977, Clinical chemistry.

[21]  G. Born,et al.  Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal , 1962, Nature.